Molecular pathways and the hope of targeting angiogenesis

Vogelzang NJ and Sternberg CN (2007) Signal-transduction inhibitors in renal cell carcinoma. BJU Int 99: 1289–1295
Article CAS Google Scholar
Mendel DB et al. (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9: 327–337
CAS PubMed Google Scholar
Motzer RJ et al. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16–24
Article CAS Google Scholar
Motzer RJ et al. (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295: 2516–2524
Article CAS Google Scholar
de Mulder PH et al. (2006) A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC). J Clin Oncol 24 (Suppl): 4529
Google Scholar

Acknowledgements

The synopsis was written by Tamsin Osborne, Freelance Medical Writer.

Department of Medical Oncology, San Camillo Forlanini Hospital, Nuovi Padiglioni, 4th floor Circonvallazione, Gianicolense 87, Rome 00152, Italy cstern@mclink.it

CN Sternberg is the Chief of the Department of Medical Oncology at San Camillo Forlanini Hospital and a Professor at La Sapienza University in Rome, Italy.,
Cora N Sternberg

Authors

The author declares no competing financial interests.

Sternberg, C. Molecular pathways and the hope of targeting angiogenesis. Nat Rev Urol 4, 470–471 (2007). https://doi.org/10.1038/ncpuro0858